STAT Plus: The race for a greater Duchenne therapy: Adam and Matt discuss Pfizer, Sarepta, and gene remedy

On Friday, Pfizer introduced the primary leads to people for its gene remedy to deal with Duchenne muscular dystrophy. Pfizer shares had been flat on the announcement, however shares in Sarepta Therapeutics, which is creating its personal therapy, elevated 18%. STAT senior writers Adam Feuerstein and Matthew Herper sat down with some extremely caffeinated drinks this morning to debate the outcomes.

Adam: Hey, Matt, the consensus appears to be that Sarepta Therapeutics has a simpler and safer gene remedy than Pfizer. That’s the large takeaway from the Pfizer presentation on Friday. How do you are feeling about that?

Unlock this text by subscribing to STAT Plus and revel in your first 30 days free!


What’s it?

STAT Plus is a premium subscription that delivers every day market-moving biopharma protection and in-depth science reporting from a staff with many years of business expertise.

What’s included?

Authoritative biopharma protection and evaluation, interviews with business pioneers, coverage evaluation, and first seems to be at innovative laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only reside chats with our reporters and specialists within the subject
Discounted tickets to business occasions and early-bird entry to business studies